Javascript must be enabled to continue!
Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission v1
View through CrossRef
Background: Proteinuria is a powerful prognostic factor for end-stage renal disease in IgA nephropathy (IgAN) patients. However, it is not known whether proteinuria exacerbations are related to seasonal changes. Methods: We retrospectively enrolled consecutive patients diagnosed with IgAN by kidney biopsy at our hospital between 2002 and 2014. Proteinuria remission was defined as urinary protein <0.3 g/gCr in two consecutive outpatient urinalyses and exacerbation as urinary protein 竕・0.75 g/gCr. Four seasons were defined: spring (March- May), summer (June- August), autumn (September- November), and winter (December- February). We performed a multivariate analysis to identify factors associated with the second remission following a proteinuria exacerbation. Results: We analyzed 116 patients. Proteinuria remission and exacerbation occurred in 89, and 50 patients, respectively. The incidence of proteinuria exacerbation was significantly higher in autumn and winter than in spring and summer (p=0.040). The cumulative second remission rate was significantly higher in patients with autumn and winter proteinuria exacerbation than in patients with spring and summer exacerbations (p=0.010). In multivariate analyses, exacerbation onset in autumn and winter (HR, 3.36; 95% CI, 1.36- 8.34) and intensive therapy (HR, 2.68; 95% CI, 1.24- 5.80) were significantly associated with a second proteinuria remission. Conclusion: In IgAN patients in proteinuria remission, proteinuria exacerbation frequently occurred in autumn and winter. Exacerbations occurring in autumn and winter tended to remit early.
Title: Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission v1
Description:
Background: Proteinuria is a powerful prognostic factor for end-stage renal disease in IgA nephropathy (IgAN) patients.
However, it is not known whether proteinuria exacerbations are related to seasonal changes.
Methods: We retrospectively enrolled consecutive patients diagnosed with IgAN by kidney biopsy at our hospital between 2002 and 2014.
Proteinuria remission was defined as urinary protein <0.
3 g/gCr in two consecutive outpatient urinalyses and exacerbation as urinary protein 竕・0.
75 g/gCr.
Four seasons were defined: spring (March- May), summer (June- August), autumn (September- November), and winter (December- February).
We performed a multivariate analysis to identify factors associated with the second remission following a proteinuria exacerbation.
Results: We analyzed 116 patients.
Proteinuria remission and exacerbation occurred in 89, and 50 patients, respectively.
The incidence of proteinuria exacerbation was significantly higher in autumn and winter than in spring and summer (p=0.
040).
The cumulative second remission rate was significantly higher in patients with autumn and winter proteinuria exacerbation than in patients with spring and summer exacerbations (p=0.
010).
In multivariate analyses, exacerbation onset in autumn and winter (HR, 3.
36; 95% CI, 1.
36- 8.
34) and intensive therapy (HR, 2.
68; 95% CI, 1.
24- 5.
80) were significantly associated with a second proteinuria remission.
Conclusion: In IgAN patients in proteinuria remission, proteinuria exacerbation frequently occurred in autumn and winter.
Exacerbations occurring in autumn and winter tended to remit early.
Related Results
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Characterization of circulating and cutaneous IgA immune complexes in patients with dermatitis herpetiformis.
Characterization of circulating and cutaneous IgA immune complexes in patients with dermatitis herpetiformis.
Abstract
Dermatitis herpetiformis (DH) is a chronic, blistering skin disease characterized in part by deposits of IgA at the dermal-epidermal junction. Eighty-five p...
Murine IgA binding factors (IgA-BF) suppressing IgA production: characterization and target specificity of IgA-BF.
Murine IgA binding factors (IgA-BF) suppressing IgA production: characterization and target specificity of IgA-BF.
Abstract
Chemical and functional properties of IgA binding factor(s) (IgA-BF) from both murine Con A-activated spleen cells and Fc gamma R+, Fc alpha R+ T hybridoma ...
Increased Frequency of Surface IgA-Positive Plasma Cells in the Intestinal Lamina Propria and Decreased IgA Excretion in Hyper IgA (HIGA) Mice, a Murine Model of IgA Nephropathy with Hyperserum IgA
Increased Frequency of Surface IgA-Positive Plasma Cells in the Intestinal Lamina Propria and Decreased IgA Excretion in Hyper IgA (HIGA) Mice, a Murine Model of IgA Nephropathy with Hyperserum IgA
AbstractBecause abnormalities of mucosal immunity have been suggested in human IgA nephropathy, we examined the involvement of mucosal immunity in IgA deposition to the kidney in h...
Etiology of IgA nephropathy syndrome
Etiology of IgA nephropathy syndrome
Since Berger's original paper on mesangial IgA‐IgG deposition with hematuria, there have been a number of clinical and pathological studies regarding IgA immune complexes, the mech...
#723 Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted−release formulation budesonide
#723 Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted−release formulation budesonide
Abstract
Background and Aims
Targeted release formulation (TRF)-budesonide (Nefecon), targeting the production of galacto...
An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti‐IgA) and IgA deficiency
An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti‐IgA) and IgA deficiency
BACKGROUND: Immunoglobulin A antibodies (anti‐IgA) are rare but can cause transfusion‐associated anaphylaxis. The detection of anti‐IgA has traditionally been performed using a lab...
Serum IgA Class Anti-IgA Antibody in IgA Nephropathy
Serum IgA Class Anti-IgA Antibody in IgA Nephropathy
IgA class anti-IgA antibody was sought by an immunoabsorbent technique in sera from patients with IgA nephropathy (IgA-N, n = 62), other forms of primary glomerulonephritis (PGN, n...

